Tonix Pharmaceuticals/$TNXP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Ticker
$TNXP
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
81
ISIN
US8902608475
Website
TNXP Metrics
BasicAdvanced
$349M
-
-$59.66
2.11
-
Price and volume
Market cap
$349M
Beta
2.11
52-week high
$130.00
52-week low
$6.76
Average daily volume
820K
Financial strength
Current ratio
12.315
Quick ratio
11.212
Long term debt to equity
0.182
Total debt to equity
0.312
Profitability
EBITDA (TTM)
-69.543
Gross margin (TTM)
29.81%
Net profit margin (TTM)
-1,313.87%
Operating margin (TTM)
-721.51%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-27.59%
Return on equity (TTM)
-91.44%
Valuation
Price to revenue (TTM)
10.392
Price to book
1.8
Price to tangible book (TTM)
1.8
Price to free cash flow (TTM)
-1.741
Free cash flow yield (TTM)
-57.45%
Free cash flow per share (TTM)
-2,711.09%
Growth
Revenue change (TTM)
-2.04%
Earnings per share change (TTM)
-99.15%
What the Analysts think about TNXP
Analyst ratings (Buy, Hold, Sell) for Tonix Pharmaceuticals stock.
Bulls say / Bears say
Tonix Pharmaceuticals' TNX-102 SL (Tonmya™) has achieved highly statistically significant and clinically meaningful results in its second positive Phase 3 clinical trial for fibromyalgia management, indicating strong potential for FDA approval and market entry. (Tonix Pharmaceuticals Press Release)
The company's diverse pipeline, including TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection, positions it to address multiple unmet medical needs, potentially leading to multiple revenue streams upon successful development. (StockTitan)
Tonix's recent public offerings have bolstered its financial position, providing necessary capital to advance its clinical programs and expand manufacturing and R&D facilities, which could accelerate product development timelines. (Tonix Pharmaceuticals Press Release)
Tonix Pharmaceuticals has faced multiple reverse stock splits, including a 1-for-100 split, to maintain NASDAQ listing requirements, reflecting ongoing challenges in sustaining its stock price above the minimum threshold. (StockTitan)
The company has experienced significant short interest growth, with a 243.1% increase in February 2025, indicating bearish sentiment among investors regarding its future prospects. (American Banking and Market News)
Analyst ratings have been mixed, with Wall Street Zen downgrading the stock to a 'sell' rating in June 2025, suggesting concerns about the company's performance and outlook. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
TNXP Financial Performance
Revenues and expenses
TNXP Earnings Performance
Company profitability
TNXP News
AllArticlesVideos
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025
GlobeNewsWire·1 week ago
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
GlobeNewsWire·1 week ago
Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tonix Pharmaceuticals stock?
Tonix Pharmaceuticals (TNXP) has a market cap of $349M as of July 19, 2025.
What is the P/E ratio for Tonix Pharmaceuticals stock?
The price to earnings (P/E) ratio for Tonix Pharmaceuticals (TNXP) stock is 0 as of July 19, 2025.
Does Tonix Pharmaceuticals stock pay dividends?
No, Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders as of July 19, 2025.
When is the next Tonix Pharmaceuticals dividend payment date?
Tonix Pharmaceuticals (TNXP) stock does not pay dividends to its shareholders.
What is the beta indicator for Tonix Pharmaceuticals?
Tonix Pharmaceuticals (TNXP) has a beta rating of 2.11. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.